Multiple Sclerosis, Relapsing Remitting Clinical Trial
Official title:
BETAEVAL_Global- The New BETACONNECT® Auto-injector: Adherence and EVALuation of MS Patients Treated With Betaferon®
Considering the significance of an early and consequent Multiple Sclerosis (MS) treatment as
well as the challenge to achieve high adherence to treatment, evaluating the benefits of any
new measure to improve adherence is important. The data storage capabilities of the
BETACONNECT device, including the automated recording of injections, will facilitate the
collection of reliable data on patient's injection behavior and adherence, which should be
unaffected by recall bias or reporting bias.
To better understand the utilities of the new BETACONNECT device and characterize its
contribution to adherence, we plan to prospectively follow-up MS patients using this device
for 24 weeks. The study will take place in a real-life setting in Neurology centers across
Europe.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT01080027 -
Safety, Tolerability and Adherence With Rebif® New Formulation in Real Life Settings (STAR)
|
N/A | |
| Completed |
NCT01080053 -
Sexual Dysfunction, Disability and Quality of Life in Patients With Multiple Sclerosis (MS)
|
N/A | |
| Completed |
NCT00859482 -
Differential Immune Effects of Natalizumab
|
N/A | |
| Completed |
NCT02638038 -
This is a Randomized Study Comparing Two Doses of INT131 ( 3 mg and 1 mg) Administered Orally (PO) Daily (QD) Versus Placebo 1 Tablet PO QD in Subjects With Treatment-naïve RRMS for ≤ 3 Years
|
Phase 2 | |
| Completed |
NCT01080040 -
To Assess the Prevalence of Spasticity and the Impact on the Quality of Life in Multiple Sclerosis Patients
|
N/A |